Article
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 2 623
approach might lead to better modifications of the pyridine
ring, affording more potent yet stable compounds.
(17) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart,
W. E.; Belew, R. K.; Olson, A. J. Automated docking using a
Lamarckian genetic algorithm and empirical binding free energy
function. J. Comput. Chem. 1998, 19, 1639–1662.
Acknowledgment. Financial support from Regione
Piemonte (Ricerca Sanitaria Finalizzata 2009 to G.C.T.)
and MiUR (PRIN contract number 2006031151_005 to
G.B.) is gratefully acknowledged. We dedicate this paper to
Prof. Aldo Martelli on the occasion of his retirement.
(18) (a) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry:
diverse chemical function from a few good reactions. Angew.
Chem., Int. Ed. Engl. 2001, 40, 2004–2021. (b) Tornoe, C. W.;
e
Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-
triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloaddi-
tions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057–
3064. (c) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B.
A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regio-
selective “ligation” of azides and terminal alkynes. Angew. Chem., Int.
Ed. 2002, 41, 2596–2599.
Supporting Information Available: Biological and chemical
experimental details, spectroscopic characterization (MS, IR,
1H and 13C NMR data) and elemental analysis of all the target
compounds, viability data for all 185 compounds in the original
screening, and molecular docking details. This material is
(19) For medicinal chemistry applications of click chemistry see:
(a) Kolb, H. C.; Sharpless, K. B. The growing impact of click
chemistry on drug discovery. Drug Discovery Today 2003, 8, 1128–
1137. (b) Tron, G. C.; Pirali, T.; Billington, R. A.; Canonico, P. L.;
Sorba, G.; Genazzani, A. A. Click chemistry reactions in medicinal
chemistry: applications of the 1,3-dipolar cycloaddition between azides
and alkynes. Med. Res. Rev. 2008, 28, 278–308.
(20) Pagliai, F.; Pirali, T.; Del Grosso, E.; Di Brisco, R.; Tron, G. C.;
Sorba, G.; Genazzani, A. A. Rapid synthesis of triazole-modified
resveratrol analogues via click chemistry. J. Med. Chem. 2006, 49,
467–470.
References
(1) Khan, J. A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine
dinucleotide metabolism as an attractive target for drug discovery.
Expert Opin. Ther. Targets 2007, 11, 695–705.
(2) Denu, J. M. The Sir 2 family of protein deacetylases. Curr. Opin.
(21) Pirali, T.; Gatti, S.; Di Brisco, R.; Tacchi, S.; Zaninetti, R.;
Brunelli, E.; Massarotti, A.; Sorba, G.; Canonico, P. L.; Moro,
L.; Genazzani, A. A.; Tron, G. C.; Billington, R. A. Estrogenic
analogues synthesized via click chemistry. ChemMedChem 2007, 2,
437–440.
Chem. Biol. 2005, 9, 431–440.
(3) Belenky, P.; Bogan, K. L.; Brenner, C. NADþ metabolismin health
and disease. Trends Biochem. Sci. 2007, 32, 12–19.
ꢁ
(4) Berger, F.; Ramırez-Hernandez, M. H.; Ziegler, M. The new life of
´
a centenarian: signalling functions of NAD(P). Trends Biochem.
Sci. 2004, 29, 111–118.
(22) (a) Pirali, T.; Pagliai, F.; Mercurio, C.; Boggio, R.; Canonico, P. L.;
Sorba, G.; Tron, G. C.; Genazzani, A. A. Triazole-modified
histone deacetylase inhibitors as a rapid route to drug discovery.
J. Comb. Chem. 2008, 10, 624–627. (b) Brik, A.; Muldoon, J.; Lin, Y.;
Elder, J. H.; Goodsell, D. S.; Olson, A. J.; Fokin, V. V.; Sharpless, K. B.;
Wong, C. Rapid diversity-oriented synthesis in microtiter plates for in
situ screening of HIV protease inhibitors. ChemBioChem 2003, 4,
1246–1248. (c) Lee, L. V.; Mitchell, M. L.; Huang, S.; Fokin, V. V.;
Sharpless, K. B.; Wong, C. A Potent and high selective inhibitor of
human R-1,3-fucosyltransferase via click chemistry. J. Am. Chem.
Soc. 2003, 125, 9588–9589.
(5) Genazzani, A. A.; Billington, R. A. NAADP: an atypical Ca2þ
-
release messenger? Trends Pharmacol. Sci. 2002, 23, 165–167.
(6) Malavasi, F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A.
L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Evolution and function of the
ADP ribosyl cyclase/CD38 gene family in physiology and pathol-
ogy. Physiol. Rev. 2008, 88, 841–886.
(7) Magni, G.; Amici, A.; Emanuelli, M.;þOrsomando, G.; Raffaelli,
N.; Ruggieri, S. Enzymology of NAD homeostasis in man. Cell.
Mol. Life Sci. 2004, 61, 19–34.
(8) Bieganowski, P.; Brenner, C. Discoveries of nicotinamide riboside
as a nutrient and conservedþNRK genes establish a preiss-handler
independent route to NAD in fungi and humans. Cell 2004, 117,
495–502.
(9) Hasmann, M.; Schemainda, I. FK866, a highly specific noncom-
petitive inhibitor of nicotinamide phosphoribosyltransferase, re-
presents a novel mechanism for induction of tumor cell apoptosis.
Cancer Res. 2003, 63, 7436–7442.
ꢀ
(23) L’Abbe, G.; Beenaerts, L. Influence of electron-withdrawing N-1
substituents on the thermal behavior of 5-azido-1,2,3-triazoles.
Tetrahedron 1989, 45, 749–756.
(24) Pizzotti, M.; Cenini, S.; Porta, F. Reactions of 2-azidopyridine and
1-pyridinio ylides with transition-metal complexes. J. Chem. Soc.,
Dalton Trans. 1978, 1155–1160.
(25) Ohira, S. Methanolysis of dimethyl(1-diazo-2-oxopropyl)pho-
sphonate. Generation of (diazomethyl) phosphonate and reaction
with carbonyl compounds. Synth. Commun. 1989, 19, 561–564.
(10) Nahimana, A.; Attinger, A.; Aubry, D.; Greaney, P.; Ireson, C.;
€
Thougaard, A. V.; Tjornelund, J.; Dawson, K. M.; Dupuis, M.;
(26) Muller, S.; Liepold, B.; Roth, G. J.; Bestmann, H. J. An improved
e
Duchosal, M A. The NAD biosynthesis inhibitor APO866 has
potent antitumor activity against hematologic malignancies. Blood
2009, 113, 3276–3286.
one-pot procedure for the synthesis of alkynes from aldehydes.
Synlett 1996, 521–522.
(27) Billington, R. A.; Travelli, C.; Ercolano, E.; Galli, U.; Roman, C.
B.; Grolla, A. A.; Canonico, P. L.; Condorelli, F.; Genazzani, A. A.
Characterization of NAD uptake in mammalian cells. J. Biol.
Chem. 2008, 283, 6367–6374.
(28) Billington, R. A.; Genazzani, A. A.; Travelli, C.; Condorelli, F.
NAD depletion by FK866 induces autophagy. Autophagy 2008, 4,
385–387.
(29) Klionsky, D. J. Autophagy: from phenomenology to molecular
understanding in less than a decade. Nat. Rev. Mol. Cell. Biol. 2007,
8, 931–937.
(30) Klionsky, D. J.; Abeliovich, H.; Agostinis, P.; Agrawal, D. K.;
Aliev, G.; Askew, D. S.; Baba, M.; Baehrecke, E. H.; Bahr, B. A.;
Ballabio, A.; et al. Guidelines for the use and interpretation of
assays for monitoring autophagy in higher eukaryotes. Autophagy
2008, 4, 151–175.
on May 25, 2009.
on May 25, 2009.
€
(13) Schou, C.; Ottosen, E. R.; Petersen, H. J.; Bjorkling, F.; Latini, S.;
Hjarnaa, P. V.; Bramm, E.; Binderup, L. Novel cyanoguanidines
with potent oral antitumour activity. Bioorg. Med. Chem. 1997, 7,
3095–3100.
€
€€
€
(14) Olesen, U. H.; Christensen, M. K.; Bjorkling, F.; Jaattela, M.;
Jensen, P. B.; Sehested, M.; Nielsen, S. J. Anticancer agent CHS-
828 inhibits cellular synthesis of NAD. Biochem. Biophys. Res.
Commun. 2008, 367, 799–804.
(15) Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C. R.; Sorba, G.;
Canonico, P. L.; Genazzani, A. A.; Tron, G. C.; Billington, R. A.
Synthesis and biological evaluation of isosteric analogues of FK866,
an inhibitor of NAD salvage. ChemMedChem 2008, 3, 771–779.
(16) Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of
human NMPRTase, a novel target for anticancer agents. Nat.
Struct. Mol. Biol. 2006, 13, 582–588.
ꢁ
(31) Beauparlant, P.; Bedard, D.; Bernier, C.; Chan, H.; Gilbert, K.;
Goulet, D.; Gratton, M. O.; Lavoie, M.; Roulston, A.; Turcotte,
E.; Watson, M. Preclinical development of the nicotinamide phos-
phoribosyl transferase inhibitor prodrug GMX1777. Anti-Cancer
Drugs 2009, 20, 346–354.